|
Nivolumab for the treatment of non-small cell lung cancer |
Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Nivolumab for the treatment of non-small cell lung cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 479. 2016 Authors' conclusions The evidence on the effectiveness and safety of nivolumab as second line treatment for advanced non-small cell lung cancer, compared with docetaxel is of high quality. Nivolumab was associated with a longer overall survival of approximately three months and a lower incidence of adverse effects. No evidence was found for first line treatment. The clinical practice guidelines of the main oncology societies consider it a therapeutic alternative for the above mentioned population. In addition, the assessed U.S. private health sponsors cover it as second line treatment in these patients. Its high cost and the lack of local evidence on its cost-effectiveness limit the possibility of making a general recommendation on its coverage at health system level. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016001131 Date abstract record published 02/12/2016 |
|
|
|